These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25275557)

  • 81. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.
    Grebely J; Hellard M; Applegate T; Petoumenos K; Yeung B; Feld JJ; Rawlinson W; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews GV;
    AIDS; 2012 Aug; 26(13):1653-61. PubMed ID: 22555168
    [TBL] [Abstract][Full Text] [Related]  

  • 82. IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System.
    Aboulnasr F; Hazari S; Nayak S; Chandra PK; Panigrahi R; Ferraris P; Chava S; Kurt R; Song K; Dash A; Balart LA; Garry RF; Wu T; Dash S
    PLoS One; 2015; 10(12):e0141655. PubMed ID: 26657215
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Alpha-interferon versus peg-interferon associated to ribavirin in the treatment of genotype 1 hepatitis C virus and human immunodeficiency virus coinfected patients].
    Almeida PR; Tovo CV; Rigo JO; Zanin P; Alves AV; Mattos AA
    Arq Gastroenterol; 2009; 46(2):132-7. PubMed ID: 19578615
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
    Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections.
    Wang T; Blatt LM; Seiwert SD
    J Interferon Cytokine Res; 2006 Jul; 26(7):473-83. PubMed ID: 16800786
    [TBL] [Abstract][Full Text] [Related]  

  • 86. CD81 expression in peripheral blood lymphocytes before and after treatment with interferon and ribavirin in HIV/HCV coinfected patients.
    Micheloud D; González-Nicolás J; Berenguer J; Lorente R; Miralles P; López JC; Cosín J; Catalán P; Muñoz-Fernández M; Resino S
    HIV Med; 2010 Mar; 11(3):161-9. PubMed ID: 19780859
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
    Younossi ZM; Birerdinc A; Estep M; Stepanova M; Afendy A; Baranova A
    J Transl Med; 2012 Feb; 10():25. PubMed ID: 22313623
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
    Dieterich D; Nelson M; Soriano V; Arastéh K; Guardiola JM; Rockstroh JK; Bhagani S; Laguno M; Tural C; Ingiliz P; Jain MK; Stern JO; Manero M; Vinisko R; Kort J;
    AIDS; 2015 Mar; 29(5):571-81. PubMed ID: 25710287
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.
    Soriano V; Maida I; Núñez M; García-Samaniego J; Barreiro P; Martín-Carbonero L; González-Lahoz J
    Antivir Ther; 2004 Dec; 9(6):987-92. PubMed ID: 15651757
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
    Seydi M; Morlat P; Bonnet F; Rambeloarisoa J; Bernard N; Lacoste D; Bonarek M; Trimoulet P; Ramanampamonjy R; Lafon ME; Dramé M; Beylot J
    Rev Med Interne; 2005 Apr; 26(4):280-7. PubMed ID: 15820563
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
    Maida I; Martin-Carbonero L; Sotgiu G; Vispo E; Barreiro P; Gonzalez-Lahoz J; Soriano V
    J Viral Hepat; 2010 Dec; 17(12):866-71. PubMed ID: 20088891
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
    Neukam K; Camacho A; Caruz A; Rallón N; Torres-Cornejo A; Rockstroh JK; Macías J; Rivero A; Benito JM; López-Cortés LF; Nattermann J; Gómez-Mateos J; Soriano V; Pineda JA
    J Hepatol; 2012 Apr; 56(4):788-94. PubMed ID: 22173157
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches.
    Ballesteros AL; Franco S; Fuster D; Planas R; Martínez MA; Acosta L; Sirera G; Salas A; Tor J; Rey-Joly C; Clotet B; Tural C
    AIDS; 2004 Jan; 18(1):59-66. PubMed ID: 15090830
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Profiles of MicroRNAs in Interleukin-27-Induced HIV-Resistant T Cells: Identification of a Novel Antiviral MicroRNA.
    Goswami S; Hu X; Chen Q; Qiu J; Yang J; Poudyal D; Sherman BT; Chang W; Imamichi T
    J Acquir Immune Defic Syndr; 2021 Mar; 86(3):378-387. PubMed ID: 33196551
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
    PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Loss of Th22 cells is associated with increased immune activation and IDO-1 activity in HIV-1 infection.
    Page EE; Greathead L; Metcalf R; Clark SA; Hart M; Fuchs D; Pantelidis P; Gotch F; Pozniak A; Nelson M; Boasso A; Gazzard B; Kelleher P
    J Acquir Immune Defic Syndr; 2014 Nov; 67(3):227-35. PubMed ID: 25314246
    [TBL] [Abstract][Full Text] [Related]  

  • 97. SAMHD1 expression in blood cells of HIV-1 elite suppressors and viraemic progressors.
    Buchanan EL; McAlexander MA; Witwer KW
    J Antimicrob Chemother; 2015 Mar; 70(3):954-6. PubMed ID: 25344600
    [No Abstract]   [Full Text] [Related]  

  • 98. Novel vaccine vectors for HIV-1.
    Barouch DH; Picker LJ
    Nat Rev Microbiol; 2014 Nov; 12(11):765-71. PubMed ID: 25296195
    [TBL] [Abstract][Full Text] [Related]  

  • 99. CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells.
    Cockerham LR; Siliciano JD; Sinclair E; O'Doherty U; Palmer S; Yukl SA; Strain MC; Chomont N; Hecht FM; Siliciano RF; Richman DD; Deeks SG
    PLoS One; 2014; 9(10):e110731. PubMed ID: 25340755
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Cellular microRNAs up-regulate transcription via interaction with promoter TATA-box motifs.
    Zhang Y; Fan M; Zhang X; Huang F; Wu K; Zhang J; Liu J; Huang Z; Luo H; Tao L; Zhang H
    RNA; 2014 Dec; 20(12):1878-89. PubMed ID: 25336585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.